Revolution Medicines Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $248.77. The average 1-year stock price forecast is 21.01% higher than the current stock price, while the lowest is $179 (-12.93%) and the highest is $320 (+55.66%).

Price Target: $248.77 (+21.01%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$179	$248.77	$248	$320
Change	-12.93%	+21.01%	+20.64%	+55.66%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	17	17	17	17	17	17
Buy	4	4	4	4	4	4
Hold	0	0	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	21	21	22	22	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ami Fadia Needham	Needham	Buy Reiterates $240 → $275	Buy	Reiterates	$240 → $275	+33.77%	Aug 31, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Maintains $291 → $315	Buy	Maintains	$291 → $315	+53.23%	Aug 29, 2026
Michael Yee UBS	UBS	Buy Maintains $220 → $265	Buy	Maintains	$220 → $265	+28.91%	Aug 28, 2026
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $215	Buy	Maintains	$215	+4.59%	Aug 27, 2026
Faisal Khurshid Jefferies	Jefferies	Buy Maintains $270	Buy	Maintains	$270	+31.34%	Aug 27, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

159.30M

Revenue Next Year

1.19B

from 159.30M

645.09%

from 159.30M

EPS This Year

-9.78

from -5.95

EPS Next Year

-6.07

from -9.78

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	29.39M	35.38M	11.58M	-	-	159.30M
Gross Profit	-157.56M	-217.69M	-407.86M	-592.23M	-987.33M	141.08M
Gross Margin	-536.09%	-615.30%	-3,522.14%	-	-	88.56%
Operating Income	-188.01M	-258.28M	-475.99M	-689.52M	-1.18B	-1.95B
Net Income	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B	-2.05B
EPS	-	-	-	-	-5.95	-9.78
Free Cash Flow	-84.69M	-132.84M	-163.95M	-347.69M	-523.28M	-1.71B
No. Analysts	-	-	-	-	-	21

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	381.3M
Avg	159.3M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	1,482.6%
Avg	645.1%
Low	285.9%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-8.35
Avg	-9.78
Low	-12.35

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-